Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789360 | 0.81 | APAF1 (0.52) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL3477429 | 0.79 | APAF1 (0.43) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL3475816 | 0.79 | HRH4 (0.46) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL2773055 | 0.79 | SENP6 (0.49) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL3476026 | 0.78 | MAPT (0.64) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL2774055 | 0.78 | MAPT (0.43) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL3474881 | 0.77 | CYP2C19 (0.49) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL2773175 | 0.77 | DRD2 (0.44) | APAF1MAPTSENP7SENP6GAA | |
| SCHEMBL3477405 | 0.77 | GAA (0.46) | NPC1RAB9AAPAF1MAPTSENP7 | |
| SCHEMBL3477427 | 0.77 | RAF1 (0.49) | APAF1MAPTSENP7SENP6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | claimed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | claimed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | HTR1A 4129/4885NPC1 4816/4885RAB9A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.